TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06661798

Intervention type: PROCEDURE
Group type: OTHER
Intervention: USG examination
Description: Comparison of blood flow in the mental foramen before and 1week, 1 month and 3 month after orthognathic surgery using ultrasound examination
Study: NCT06273111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% simvastatin ointment
Description: 5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
Study: NCT04187040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Study intervention: 3-step hand hygiene technique
Description: 3-step hand hygiene technique:~1. Covering all surfaces of the hands (based on own judgement)~2. Rotational rubbing of fingertips in the palm of the alternate hand~3. Rotational rubbing of both thumbs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention: 6-step hand hygiene technique
Description: 6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~1. Rubbing hands palm to palm~2. Palm to palm with fingers interlaced~3. Right palm over left dorsum with interlaced fingers and vice versa~4. Back of fingers to opposing palms with fingers interlocked~5. Rotational rubbing of left thumb clasped in right palm and vice versa~6. Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa
Study: NCT06348836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Description of exercises are noted in the arms/groups descriptions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Description of exercises are noted in the arms/groups descriptions
Study: NCT05666843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Dietary Advice
Description: Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care.The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
Study: NCT06209788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental group
Description: The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
Study: NCT06661798

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subjective evaluation - Neuro-sensitivity tests
Description: Direction determination, two-point separation, pinprick, and brush tests, along with neurosensitivity VAS and pressure VAS, were applied to the patients. These tests were performed before surgery (T0), seven days after surgery (T1), one month after surgery (T2), and three months after surgery (T3).
Study: NCT06665230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Oral administration
Study: NCT04768972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION363
Description: ION363 will be administered by IT bolus injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by IT bolus injection.
Study: NCT05283239

Intervention type: OTHER
Intervention: Follow up
Description: Participants will be followed up at 6th，12th, 18th and 24th months with HPV viral integration/genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
Study: NCT06668857

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: video-oculography
Description: All participants will receive quantitative oculomotor and pupillomotor measurements using two different video-oculography devices. Thereby both pursuit eye movements, saccades and pupillary responses to light will be assessed. In addition, there will be a quantitative assessment of the angular vestibulo-ocular reflex (aVOR) by use of video-head-impulse testing and a hearing test.
Study: NCT06588751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scalp block
Description: After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.

Intervention type: OTHER
Group type: OTHER
Intervention: Scalp block
Description: After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
Study: NCT06665373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: The Atkins diet is a low-carb eating plan that focuses on balancing protein, fat, and carbohydrates.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness Program
Description: 12 weeks of two weekly supervised exercise sessions combined with an individualized home exercise program based on physical capabilities and available equipment.
Study: NCT06665061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCV
Description: Patients were randomly assigned to receive PCV mechanical ventilation, with consistent ventilation parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCV
Description: Patients were randomly assigned to receive VCV mode mechanical ventilation, with consistent ventilation parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRVC
Description: Patients were randomly assigned to receive PRVC mode mechanical ventilation, with consistent ventilation parameters.
Study: NCT06666283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 150μg
Description: AP303 Tablet 150μg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 300μg
Description: AP303 Tablet 300μg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 150μg
Description: Placebo Tablet 150μg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300μg
Description: Placebo Tablet 300μg QD
Study: NCT06666712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan (TPT) is a chemotherapeutic agent that is a topoisomerase inhibitor. This intervention is uniquely distinguished through its administration using an externalized catheter and external microinfusion pump (Convection-Enhanced Delivery)
Study: NCT06667739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT-L3
Description: The intervention is a physical activity behaviour change intervention: IMproving Physical Activity through Coaching and Technology following Lower Limb Loss (IMPACT-L3). Two theories provide a framework for IMPACT-L3. One is social cognitive theory and the other is self-determination theory. As mHealth solutions have the potential to increase access and improve health outcomes, IMPACT-L3 will be delivered entirely virtually.
Study: NCT04218331

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROMPT
Description: PROMPT is a multidimensional oral-motor approach to speech production disorders.
Study: NCT06666530

Intervention type: OTHER
Intervention: Questionary
Description: Three self-questionnaires, either completed independently or with assistance, will be administered at inclusion (between the first obstetric ultrasound and 28 weeks of amenorrhea), during the third trimester of pregnancy, and at 1 year postpartum
Study: NCT06666309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBCM-PrEP + Text Messaging
Description: Two sessions Strengths-Based Case Management intervention adapted for HIV PrEP related educational content delivered to individual clients in the syringe service program setting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBCM-PrEP + Text Messaging
Description: Two sessions Strengths-Based Case Management intervention adapted for HIV PrEP related educational content delivered to individual clients in the syringe service program setting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBCM-PrEP + Text Messaging
Description: Two sessions Strengths-Based Case Management intervention adapted for HIV PrEP related educational content delivered to individual clients in the syringe service program setting
Study: NCT05016349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All trans-retinoic acid
Description: Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All trans-retinoic acid
Description: Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All trans-retinoic acid
Description: Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-Cis Retinoic Acid plus Tocopherol
Description: 13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-Cis Retinoic Acid plus Tocopherol
Description: 13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200mg capsules daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200mg capsules daily for 28 days
Study: NCT06666309

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC-PrEP + Text Messaging
Description: 1 session PrEP education based on CDC guidelines delivered to individual clients in syringe service program settings

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CDC-PrEP + Text Messaging
Description: 1 session PrEP education based on CDC guidelines delivered to individual clients in syringe service program settings

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CDC-PrEP + Text Messaging
Description: 1 session PrEP education based on CDC guidelines delivered to individual clients in syringe service program settings

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: T-SBCM
Description: Up to two post-linkage sessions of SBCM delivered by a peer support specialist in a format of the participants' choice (onsite, virtual/phone) in study month 2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-SBCM
Description: Up to two post-linkage sessions of SBCM delivered by a peer support specialist in a format of the participants' choice (onsite, virtual/phone) in study month 2

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile Outreach
Description: Up to two in-person field session visits will be conducted by a peer support specialist for the purpose of offering direct support to arrange joint activities for overcoming identified barriers (e.g., transportation) to PrEP care initiation in study month 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Outreach
Description: Up to two in-person field session visits will be conducted by a peer support specialist for the purpose of offering direct support to arrange joint activities for overcoming identified barriers (e.g., transportation) to PrEP care initiation in study month 2.
Study: NCT06665711

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3% Hypertonic Saline
Description: In this arm of the study, participants will receive nebulized 3% hypertonic saline as the primary treatment for bronchiolitis. The administration of hypertonic saline is aimed at reducing airway edema and improving mucociliary clearance in infants experiencing respiratory distress due to bronchiolitis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention: Salbutamol (Ventolin)
Description: In this arm of the study, participants will receive nebulized Salbutamol, a bronchodilator commonly used in the management of bronchospasm associated with respiratory conditions, including bronchiolitis. The objective is to evaluate the effectiveness of Salbutamol in comparison to 3% hypertonic saline in improving the clinical outcomes of infants with bronchiolitis.
Study: NCT06670508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane block
Description: Group A, The patient was in the supine position then; the TAP block was given by a high frequency linear ultrasound transducer (Siemens acuson x300 3-5MHz ultrasound). After skin preparation and isolation, the transducer was placed 2 cm sub-xiphoid, then moved along the subcostal edge to identify the rectus abdominis muscle and the transversus abdominis then, a blunted tip, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) was introduced in-plane 2-3 cm lateral to the transducer, under direct ultrasound visualization. After confirming the correct placement of the needle and the negative aspiration probe, the rest of the anaesthetic substance was injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine on each side after aspiration to avoid intravascular placement, and the dissection of the plane was observed. The block was performed bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block
Description: Group B, the patient was placed in the prone position. Then, the Erector Spinae block was given by same ultrasound transducer . It was sagittaly placed against the target vertebral level (T7 transverse process) in the prone position and moved in approximately 3-cm lateral to the spinous process.. The Erector Spinae muscle and transverse process was identified, and a same blunted tip , 20-gauge, short bevel needle was advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane. The block was performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally.
Study: NCT06597448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Postpartum Depression (PPD)
Description: Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). The intervention consists of 9- 2hr sessions, the first half involves teaching and practice of CBT skills (cognitive restructuring, thinking errors, problem solving etc) followed by one hour of unstructured discussion around topics relevant to participants with Postpartum Depression (PPD) (sleep, supports, transitions, etc). Each group will be delivered by one randomly selected PHN and one randomly selected peer using our intervention manual.
Study: NCT06545669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-Raven Virtual Tobacco Cessation Counseling
Description: A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Product
Description: Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening
Description: After participating in shared decision-making, eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
Study: NCT04940286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Given IV
Study: NCT06622928

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiographic Assessments:~Pre-Hemodialysis Echocardiography:~Before each hemodialysis session, echocardiograms will be performed to evaluate cardiac function and gather baseline data on ventriculo-arterial coupling (VAC) parameters. This will include recording three apical echocardiographic views (4-chamber, 2-chamber, and 3-chamber) by a trained sonographer.~Post-Hemodialysis Echocardiography:~Following the completion of the hemodialysis session, echocardiographic assessments will be repeated to measure changes in VAC parameters and other relevant cardiac metrics.
Study: NCT06684197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine will be given as a bolus (0.5 μg.kg-1) over 10 minutes. A perfusion of 0.5 mcg.kg-1.h-1 of dexmedetomidine will be programmed and maintained up until the pneumoperitoneum is deflated or up until a total dose of 2.5μg.kg-1 has been administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be used instead of dexmedetomidine
Study: NCT06484829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purinostat Mesylate 3mg/m2
Description: 3 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purinostat Mesylate 3mg/m2
Description: 3 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purinostat Mesylate 4 mg/m2
Description: 4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purinostat Mesylate 4 mg/m2
Description: 4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purinostat Mesylate 6 mg/m2
Description: 6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purinostat Mesylate 6 mg/m2
Description: 6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purinostat Mesylate 8.4 mg/m2
Description: 8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purinostat Mesylate 8.4 mg/m2
Description: 8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
Study: NCT06214078

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nicotinamide mononucleotide
Description: Nicotinamide mononucleotide (NMN), a bioactive substance found in a variety of foods, is a precursor for the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ plays a crucial role in a variety of biological processes including cell death, senescence, gene expression, neuroinflammation, and DNA repair.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo mimicked the appearance and properties of nicotinamide mononucleotide(NMN) enteric-coated capsules. The specifications, usage and dosage of placebo were the same as those of NMN.